Inhibikase Therapeutics (IKT) Depreciation & Amortization (CF) (2022 - 2025)

Inhibikase Therapeutics (IKT) has 4 years of Depreciation & Amortization (CF) data on file, last reported at $23688.0 in Q3 2025.

• On a quarterly basis, Depreciation & Amortization (CF) rose 260.66% year-over-year to $23688.0 in Q3 2025; TTM through Mar 2026 was $47845.0, a 47.86% increase from a year earlier, with the FY2025 full-year figure at $60499.0, up 130.28% from the prior year.
• Depreciation & Amortization (CF) for Q3 2025 stood at $23688.0, down from $24157.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for IKT reached as high as $159204.0 in Q2 2023 and fell as low as $1681.0 in Q3 2022.
• Historically, Depreciation & Amortization (CF) has averaged $20836.7 across 4 years, with a median of $6568.0 in 2023.
• Across the five-year window, Depreciation & Amortization (CF) soared 290.72% in 2023 and sank 95.87% in 2024, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $5042.0 in 2022, then soared by 30.27% to $6568.0 in 2023, then slipped by 0.02% to $6567.0 in 2024, then jumped by 260.71% to $23688.0 in 2025.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $23688.0 in Q3 2025, $24157.0 in Q2 2025, and $12654.0 in Q1 2025.